Drugs / Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03970096 | Nov 2019 → Dec 2027 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic CD34+-enriched and CD45RA-depleted PBSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03970096 ↗ |
| Route | Intravenous | “Given IV” NCT03970096 ↗ |